Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma

Chen, Chien Pong

doi:10.14218/jcth.2018.00060

Cited by 46 publications

(34 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMRT is an advanced technique that uses modulated beams which allow for more improved target coverage, more conformal radiation dose distribution, and better radiation dose sparing of critical normal structures other than the liver. The effectiveness of postoperative adjuvant RT in reducing the recurrence and improving the OS has been well documented in various studies [26][27][28][29][30]. Moreover, adjuvant RT following hepatectomy could efficiently improve the relapse free survival (RFS) and overall survival (OS) in HCC patients with MVI compared with TACE [21,22].…”

Section: Introductionmentioning

confidence: 99%

Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study

Wang

Rong

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Microvascular invasion (MVI) is considered to be one of the important prognostic factors that affect postoperative recurrence in patients with hepatocellular carcinoma (HCC) with variable results across their treatment options. This study was carried out to investigate efficacy of postoperative adjuvant RT in HCC patients with MVI. Methods: This was single center, prospective study carried out in HCC patients with MVI, aged 35-72 years. All patients were non-randomly allocated to receive standard postoperative treatment of HBV/HCV and nutritional therapy or RT in addition to standard postoperative treatment (1:1). The primary endpoints assessed were relapse-free survival and overall survival. The prognostic factors associated with survival outcomes were also analyzed. The safety events were graded according to NCI-CTCAE v4.03 criteria. Results: Of the 115 patients eligible for study, 59 patients were included in analysis. Univariate analysis revealed that MVI classification (P = 0.009), post-operative treatment strategies (P = 0.009) were prognostic factors for worst RFS; tumor size (P = 0.011), MVI classification (P = 0.005) and post-operative treatment (P = 0.015) were associated for OS. The 1-, 2-, 3-year RFS rates were 86.2, 70.5 and 63.4% for patients in RT group, and 46.4, 36.1, and 36.1% in control group. For OS, corresponding rates were 96.6, 80.7, and 80.7% for patients in RT group and 79.7, 58.3, and 50.0% in control group. Subgroup classification of HCC patients according to low risk MVI showed significantly longer RFS (P = 0.035) and OS (P = 0.004) in RT group than control group, while for high risk MVI, RT depicted longer OS than control group with no significance (P = 0.106). Toxicities were usually observed in acute stage with no grade 4 toxicities.

show abstract

Section: Introductionmentioning

confidence: 99%

Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study

Wang

Rong

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, accounting for ~85% of all cases (36). The high mortality rate of liver cancer is mainly associated with tumor invasion, metastasis and tumor recurrence after surgical resection (6,37). In recent years, a number of studies have confirmed that the CSN superfamily is widely involved in the regulation of several important intracellular pathways, including cell proliferation, migration, invasion and signal transduction, and plays an important role in tumor development (13,(38)(39)(40).…”

Section: Discussionmentioning

confidence: 99%

CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression

Zhang

Yin

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Constitutive photomorphogenesis 9 signalosome subunit 1 (CSN1) plays an important role in the ubiquitin-proteasome pathway and regulates various cellular processes, such as the cell cycle and DNA repair. The CSN complex consists of eight subunits (CSN1 to CSN8) and regulates the tumorigenesis of a variety of tumor types. However, the exact role of CSN1 in hepatocellular carcinoma (HCC) remains unclear. The present study evaluated the expression and biological effects of CSN1 in HCC tissue samples and cell lines. CSN1 was significantly overexpressed in HCC tissue and cell lines, compared with their normal counterparts. In patients with HCC, elevated CSN1 levels correlated with tumor size, tumor metastasis and tumor stage. Loss-of-function assays indicated that CSN1 knockdown inhibited the proliferation and migration HCC cells. In addition, CSN1 promoted the expression of cyclin A2 in a ubiquitination-independent manner. Lastly, xenograft experiments indicated that CSN1 promoted HCC tumor growth in vivo . The present study suggested that CSN1 inhibition could represent a potential approach for the prevention of HCC progression and metastasis.

show abstract

“…Due to the high malignancy, high invasive potential, and early metastasis onset of HCC, many patients are unable to receive radical resection in a timely manner (32,35). The high mortality rate of patients is due mainly to tumor invasion, metastasis and recurrence after surgical resection (36,37). Researchers are urgently exploring therapeutic targets to improve the diagnosis and treatment of HCC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma

Chang

Yeh

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Hepatocellular carcinoma (HCC) is a particularly malignant form of cancer prevalent throughout the world; however, there is a pressing need for HCC biomarkers to facilitate prognosis and risk assessment. Patients and Methods: This paper reports on the potential prognostic value of WNK lysine deficient protein kinase 1 (WNK1) in cases of HCC. We analyzed the expression of WNK1 at the mRNA level using omics data from the UALCAN database. We then verified our findings through the immunohistochemical (IHC) staining of various human cancer tissue as well as 59 HCC samples paired with corresponding normal tissues. The prognostic value of mRNA or protein expression by WNK1 was evaluated using the Kaplan-Meier method. Results: Initial screening results revealed significantly higher WNK1 expression levels in HCC tissue compared to normal tissue. Verification using the paired HCC samples confirmed that the expression of WNK1 was indeed significantly higher in HCC tissue samples than in adjacent normal tissues. High WNK1 expression levels were significantly correlated with clinicopathological variables, including gender and histologic grade. Kaplan-Meier survival analysis revealed that high WNK1 expression levels were associated with poor HCC prognosis. Finally, univariate and multivariate analysis identified WNK1 as a prognostic factor for TNM stage in cases of HCC. Conclusion: In summary, WNK1 is overexpressed at the mRNA and protein levels, and correlated with poor prognosis. Thus, WNK1 expression could potentially be used as a biomarker in HCC prognosis. Hepatocellular carcinoma (HCC) is responsible for an enormous number of cancer-related deaths, particularly in sub-Saharan Africa and Southeast Asia (1, 2). HCC is among the deadliest forms of cancer, and the treatment of HCC has been well demonstrated in multiple series, with an overall 5year survival rate between 33% and 55% (3). The most common risk factors include infections with hepatitis B virus (HBV) or hepatitis C virus (HCV), chronic exposure to aflatoxin B (AFB1), excessive alcohol consumption (EAC), non-alcoholic steatohepatitis (NASH), and metabolic syndrome (METS). HCC commonly progresses from chronic liver inflammation and cirrhosis, which eventually trigger the formation of liver tumors (4, 5). The fact that the early symptoms of HCC are not obvious means that at the time of diagnosis, most patients are in the middle or late stages of the disease (i.e., beyond the window for surgery). Note that 50% of patients who undergo radical surgical 2631 This article is freely accessible online.

show abstract

Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma

Cited by 46 publications

References 105 publications

Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study

Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study

CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression

Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma

Contact Info

Product

Resources

About